Irbesartán /Hidroclorotiazida Sandoz (Hydrochlorothiazide, Irbesartan)

Irbesartán / Hidroclorotiazida Sandoz is used in the management of hypertension, a condition characterized by persistently high arterial pressure.

• Essential hypertension: provides combined reduction of vascular resistance and plasma volume to achieve target blood pressure.
• Hypertension requiring diuretic therapy: adds diuretic effect to improve blood pressure control when additional volume reduction is needed.
• Hypertension in patients intolerant to monotherapy: offers an alternative to escalating single‑agent doses.

• Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, which lowers systemic vascular resistance. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit NaCl reabsorption, increasing urinary excretion of sodium and water, thereby reducing plasma volume. The combined actions result in synergistic blood‑pressure lowering effects.

Common Side Effects

• Dizziness: light‑headed sensation, especially after standing.
• Headache: mild to moderate intensity.
• Increased urination: due to diuretic action.
• Electrolyte imbalance: low potassium or sodium levels.
• Fatigue: general feeling of tiredness.
• Mild gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Angioedema: rapid swelling of face, lips, tongue, or throat.
• Significant hypotension: marked drop in blood pressure causing faintness.
• Acute kidney injury: reduced renal function requiring medical attention.
• Hyperkalemia: dangerously high potassium levels.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Pregnancy: category D; avoid use unless benefits outweigh risks.
• Renal impairment: assess kidney function and adjust therapy as needed.
• Electrolyte disturbances: monitor serum potassium and sodium regularly.
• Concomitant potassium‑sparing agents: increased risk of hyperkalemia; use with caution.
• Alcohol: may potentiate hypotensive effects; advise moderation.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Irbesartán / Hidroclorotiazida Sandoz may interact with several medicines.

Major Interactions (Avoid)

• Potassium supplements or potassium‑sparing diuretics: risk of severe hyperkalemia.
• ACE inhibitors or aliskiren in pregnancy: additive effects on the renin‑angiotensin system.
• NSAIDs: may diminish antihypertensive efficacy and affect renal function.

Moderate Interactions (Monitor Closely)

• Lithium: increased lithium concentrations, risk of toxicity.
• Digoxin: heightened risk of digoxin toxicity.
• CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan plasma levels.